Society of Investment Professionals in Germany

Going East / Going West

Life Science Asia/Europe –

getting insight in mutual growth opportunities

4thDVFASymposiumLifeSciencefollowedbyaGetTogether

17May2011,from9a.m.

DVFA Center, Frankfurt/Main

4thDVFALifeScienceConference

Supported by

Media Partner

Life Science Conference

Dear attendee, DVFA Committee Life Science is proud to present the 4th DVFA Life Science Conference in Frankfurt/Main. The 4th DVFA Symposium Life Science focuses on growth opportunities and challenges for European companies ("Going East") and Asian companies ("Going West"). Many European life science companies are currently expanding their strategic market position in Asia via acquisitions, cooperations etc. to participate in the fast growing Asian life science markets. On the other side some Asian companies are keen to grow internationally and/or to get access to the German capital market. I am very pleased to welcome you in Frankfurt and wish you an interesting and informative conference. If there is anything DVFA can do to make you feel more comfortable, or if you have questions, please do not hesitate to contact myself or my team any time. Kind regards, Ralf Frank MBA Managing Director DVFA GmbH

1

Life Science Conference

DISCLAIMER

This brochure contains information from sources believed to be reliable but has not been verified or testified. The corporate data provided has been transmitted and converted electronically. Therefore, the information cannot be guaranteed to be secure or error-free as the transmitted and converted information could be intercepted, corrupted, lost or incomplete.

Thus, DVFA does not accept liability for any errors or omissions regarding the contents of this information. The conference brochure is provided for information purposes and should not be construed as a solicitation or offer to buy or sell any securities or related financial instruments.

Any copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

Please note that the data given in this brochure may be rounded. Deviations may thus occur, e.g. regarding percentage figures.

2011 DVFA GmbH

ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher and the copyright holder.

Editorial Close: 13 May 2011

2

Life Science Conference

Society of Investment Professionals in Germany

Table of Contents

Page

Programme Symposium ............................................................................................................. 5

Speakers and Moderators .......................................................................................................... 6

Sponsors .................................................................................................................................... 13

Media Partner ............................................................................................................................ 18

Organizational Notes ................................................................................................................ 19

3

Life Science Conference

Programme Symposium

Tuesday, 8 June 2010

09:15 Check-in 09:30 Welcome Ralf Frank, Managing Director, DVFA GmbH Dr. Christa Bähr, DZ BANK AG and Chairwoman DVFA Commission Life Science 09:40 Going East in Life Science - An introduction Dr. Martin Schloh, PricewaterhouseCoopers AG, Partner, Head of Pharma & Healthcare Consulting Practice in Germany 10:15 QIAGEN N.V. Victor Shi, President Asia Pacific 10:50 Miltenyi Biotec GmbH Dr. Boris Stoffel, Managing Director 11:25 Coffee Break 11:40 Sanofi Pasteur Pierre Morgon, VP, Franchise & Global Marketing Operations 12:15 Panel I:

Going-East – Growth Opportunities and Challenges for European Life Science Companies

Kai Brüning, apo Asset Management GmbH Pierre Morgon, Sanofi Pasteur Dr. Martin Schloh, PricewaterhouseCoopers AG Dr. Boris Stoffel, Miltenyi Biotec GmbH Moderation: Dr. Markus Manns, Union Investment Privatfonds GmbH 13:15 Lunch 14:00 China – A Growth Opportunity for Western Pharmaceutical Companies Andrew Baum, Managing Director Equity Research, Morgan Stanley 14:35 Going West of Chinese Life Science Companies - An Introduction Dr. Songjie Liu, GCTex GmbH, Managing Director 14:55 Transaction Structures Dr. Ulrike Binder, Partner, Mayer Brown LLP 15:15 Coffee Break 15:30 Mindray Medical Germany GmbH Anders Bang, Managing Director 16:05 Panel II:

Going West – Is the German Capital Market ready for Asian Life Science Companies? Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP Sunghee Cho, Managing Director, RNL Bio Alexander von Preysing, Deutsche Börse AG Moderation: Kersten Schmitz, DZ BANK AG 17:00 Get Together

Subject to modifications!

5

Life Science Conference

Speakers & Moderators Dr. Christa Bähr, DZ BANK AG

Anders Bang, Mindray Medical Germany GmbH

Andrew Baum, Morgan Stanley

Dr. Ulrike Binder, Partner, Mayer Brown LLP

Kai Brüning, apo Asset Management GmbH

Sunghee Cho, RNL Bio

Dr. iur. Dr. med. Adem Koyuncu, Mayer Brown LLP

Dr. Songjie Liu, GCTex GmbH

Dr. Markus Manns, Union Investment Privatfonds GmbH

Pierre Morgon, Sanofi Pasteur

Dr. Martin Schloh, PricewaterhouseCoopers AG

Kersten Schmitz, DZ BANK AG

Victor Shi, QIAGEN N.V.

Dr. Boris Stoffel, Miltenyi Biotec GmbH

Alexander von Preysing, Deutsche Börse AG

The following information is provided by the respective speakers and moderators. DVFA cannot assume any responsibility for the correctness and completeness of this information.

6

Life Science Conference Dr. Christa Bähr, CEFA, CFA, DZ BANK AG & Chairwoman DVFA Committee Life Science

Christa Bähr joined DZ BANK Equity Research in January 2000 to build up the Life Science Team. In July 2003 she became group leader of the newly founded group which includes Life Science, Chemicals, Telecoms, Real Estate and Financials. Besides she is in her position as lead analyst healthcare responsible for the fundamental analysis of healthcare stocks. She is CEFA Investment Analyst/DVFA und Chartered Financial Analyst (CFA) and chairwoman of the DVFA Commission Life Science. Following an apprenticeship as bank clerk at Commerzbank AG, she studied

business administration and economics at the University of Cologne. After that she worked as an assistant at the Seminar for Public Finance at the University of Cologne and obtained her doctorate in economics (Dr. rer. pol.) in 1994. Before and during her studies, she worked for Commerzbank AG in Bonn, Cologne and London. From 1994 to 1998, she worked for Bankgesellschaft Berlin AG in Berlin, and from 1998 to 1999 for BHF-BANK AG/ING Group in Frankfurt as investment analyst for pharmaceutical, healthcare, biotechnology and chemical stocks. Dr. Ulrike Binder, Partner, Mayer Brown LLP

Ulrike Binder is an experienced, highly respected transactional lawyer whose practice is concentrated on corporate and equity capital markets. Her areas of particular focus include initial public offerings, secondary offerings, private placements, public take-overs, going private, and corporate restructuring. Ulrike advises clients — including listed companies, issuers, and

underwriters — across a broad range of corporate and capital markets topics. She provides in-depth counsel regarding domestic and EU securities law, investment regulations, issues of corporate and institutional liability, risk-mitigation, and governance practices. In 2010 Ulrike was named Top 25 Corporate Lawyer by the German magazine WirtschaftsWoche. Prior to joining Mayer Brown in 2004, Ulrike worked with another major law firm in Frankfurt. She has authored several authoritative articles for professional journals and is fluent in German, English and French. Kai Brüning, apo Asset Management GmbH

Kai Brüning is a Senior Portfolio Manager at apo Asset Management, which is a majority owned subsidiary of Deutsche Apotheker & Ärztebank. He manages global healthcare funds for institutional and private clients. Mr. Brüning works in the healthcare investment area for over a decade. Before joining apo Asset he worked with ADIG/ Cominvest and Deka Investment. Mr. Brüning holds a Diplom-Kaufmann degree from the University of Cologne and is a DFVA/CEFA degree holder. He was awarded by Thomson Extel surveys in the past and is a board member of the DVFA Life Science Commission.

7

Life Science Conference Sunghee Cho, RNL Bio

Ms. Sunghee Cho is an expert in strategy, market analysis, and business development and brings in about 15 years of experience as consultant to diverse international clients. Her professional background includes from senior level position at IHS CERA in US to project manager at TSB Technology Foundation Berlin. Ms. Cho was a founding partner and managing director of a biotechnology start up located in Berlin, Germany, from which she made a successful exit by selling her shares to a strategic

investor in 2010. Currently, Ms. Cho advises RNL Bio Co. Ltd of South Korea on its global business development. She has degrees in mathematics and economics from Georgetown University and studied graduate course in economics at Harvard University. Dr. iur. Dr. med. Adem Koyuncu, Mayer Brown LLP

Dr. Dr. Adem Koyuncu is double qualified as lawyer and medical doctor and is one of the co-chairs of Mayer Brown’s global Life Sciences-practice. He focuses his practice on advising and representing Life Sciences industry clients. His clients include midsize and global and some of the leading pharmaceutical, medical devices and nutrition companies. He also advises investors in the Life Sciences-industry. Prior to joining Mayer Brown, Adem worked for several years in the pharma

industry and practiced as medical doctor. He has an in-depth knowledge of the Life Sciences industry. Adem assists clients in transactions and corporate matters. He also provides advice on compliance, regulatory and liability matters. In 2008 and 2005, he received renowned awards for his legal work. He is named as "often recommended lawyer" for pharma and medical devices law by Germany’s leading legal handbook. Adem is the author of numerous publications and a frequent speaker on Life Sciences industry related topics. He is a lecturer at the Bucerius Law School and the University of Düsseldorf. Adem is fluent in German, Turkish and English.

8

Life Science Conference Dr. Songjie Liu, GCTex GmbH Working experiences: Since 2006 managing director in Berlin consulting company,

German Chinese Technology (GCTex) GmbH in Berlin

2003 – 2005 molecular medicine senior scientist in Max Planck Institute, Goettingen

2000 – 2003 biomedical senior scientist in Queen’s Medical Centre, England

1999 – 2000 research scientist in Charite (Humboldt University Hospital), Berlin

1994 – 1999 PhD Student in University Münster, Germany 1992 – 1994 Stipendiat in University Giessen, Germany 1990 –1992 research scientist in Southern China University, Guangzhou, China 1987 –1990 university Lecturer in Tianjin, China Education: 10/1994 – 06/1999 PhD degree in Molecular biology in University Münster, Germany 09/1984 – 08/1987 Master Degree in Biology in Northwestern University, China 09/1980 – 08/1984 Bachelor Degree in Biologie in Northwestern University, China Dr. Markus Manns, Union Investment Privatfonds GmbH

Markus Manns joined Union Investment in 2000 as Portfolio Manager Life Sciences. He manages the award winning funds Unisector Biopharma and Unisector Gentech and is also Co-chairman of the DVFA Commission Life Science and member of the advisory board of Go-bio, a start-up program from the Federal Ministry of Education and Research (BMBF). Markus Manns graduated from Johannes Gutenberg University Medical School Mainz in 1993 and received his doctorate degree in medicine the same year. From 1993-1995 he worked as a Research Fellow at Thomas

Jefferson University in Philadelphia and published several scientific papers in the area of acute renal failure and hemodialysis. He worked from 1996-1998 as Product Manager Acute Therapies at Fresenius Medical Care in Bad Homburg and Milano and from 1999-2000 as Senior Consultant for Gemini Consulting in Bad Homburg.

9

Life Science Conference Pierre Morgon, Sanofi Pasteur

Pierre A. MORGON received his Doctorate of Pharmacy from the University of Lyon in 1985, his Masters in Business Law from the Lyon Law School in 1986 and his MBA from ESSEC in Paris in 1988. He is also an alumnus of INSEAD, IMD and MCE executive programs. He is a member of the Management Center Europe Sales & Marketing Council, and he has been a lecturer in pharmaceutical and biotechnology industry seminars and in business schools for several years. Pierre MORGON has over 24 years experience in the pharmaceutical industry, in marketing and operations positions as Product Manager,

International Group Product Manager, International Marketing Director, Vice President Marketing, VP Business Unit, General Manager and VP Global Marketing Operations. Through these local and global positions, he has acquired direct experience with blockbuster products in diverse markets (primary care, specialty care, hospital, vaccines, and biotechnology) and many geographies. He spent 2 years at ICI-Pharma, followed by 8 years at Synthelabo, a division of L’Oreal. Subsequently, he joined Aventis Pasteur in 1998, as VP Marketing, International, and was promoted to Vice President Global Product Marketing. Then he had a diversified and complementary set of experiences in operations, first at Yamanouchi Pharma France as General Manager, then at BMS France as Vice President, Hospital Operations, then at Schering-Plough as Director of the Primary Care business unit in France, and eventually at BioAlliance Pharma as Chief Operating Officer and Member of the Management Board. In June 2009, he joined Sanofi Pasteur as Vice President, Franchise & Global Marketing Operations, and member of the Executive Committee.

10

Life Science Conference Dr. Martin Schloh, PricewaterhouseCoopers AG Berufserfahrung seit 2010 PwC, Partner 2006-2010 A.T. Kearney, Partner 1998-2006 Roland Berger Strategy Consultants, Partner bis 1998 Bayer AG Akademischer Hintergrund 1990 Promotion (Dr.) 1983-1990 Studium der Chemie, Massachusetts Institute of Technology (MIT) Relevante Projekterfahrung (Multi-) Projektmanagement • Projektorganisationen globaler Launch-Projekte • Mehrere Post Merger Integrationen führender internationaler Pharmaunternehmen in

Deutschland und Europa Restrukturierung • Restrukturierung und Reorganisation mehrerer führender Pharmaunternehmen und

spezialisierter Medtechunternehmen Businessplanung • Businessplanung für Krankenhausbau in Emerging Markets • Commericial Due Diligences für Pharma-, Generika-, Dialyse-, Diagnostikunternehmen und

Altenheimbetreiber in Deutschland, Frankreich, Schweden, Polen und Rumänien • Geschäftsmodellentwicklung und Businessplanung für verschiedene führende Pharma- und

Medizintechnikunternehmen • Verschiedene Commcerial Due Diligences und Businessplananalysen Kersten Schmitz, DZ BANK AG

Kersten Schmitz has been working in investment banking for more than 20 years. As Head of Equity Capital Markets at DZ BANK AG, he is responsible for the whole equity product universe offered to companies both from Germany and from a variety of countries abroad. The assignments he is in charge of comprise initial public offerings, capital increases and secondary placements, and mezzanine financing such as participatory certificates. In addition, the product range encompasses corporate advisory, public takeover offers and fairness opinions as well as corporate broking mandates which include, inter alia, designated

sponsoring activities and share buybacks. Mr Schmitz holds a degree in business administration (Diplom-Kaufmann) from Cologne University. He started his business career at Commerzbank. After seven years, he joined Sal. Oppenheim where he worked for fifteen years in the Equity Capital Markets department leaving as a Senior Vice President responsible for the syndicate desk and transactions in the sectors financial institutions and real estate.

11

Life Science Conference Victor Shi, QIAGEN N.V.

Dr. Victor Shi is Asia Pacific President of QIAGEN, a publicly-listed world leading provider of sample and assay technologies in the field of molecular diagnostics. Dr. Shi heads QIAGEN’s commercial operations and strategic development in Asia and manages an organization with over 500 employees in 11 subsidiaries. Dr. Shi has over 17 years’ experience in life science business development, management and investment. Previously held positions include Managing Partner, Aura Partners (Shanghai and Hong Kong),

Senior Vice President of Corporate Development, Bridge Pharmaceuticals (Menlo Park, California), Managing Director of Discovery Resources Group (Palo Alto, California), Vice President of Corporate Development at Genospectra (Fremont, California), and Director of Asia Operations at A. M. Pappas & Associates (Singapore). He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co. Dr. Shi holds Ph.D. and M.S. degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China. Alexander von Preysing, Deutsche Börse AG

Alexander von Preysing joined Deutsche Börse in 1996. He was member of the core team that launched Neuer Markt, by the end of the last decade Europe’s leading technology market. He was Co-Founder of NeuerMarkt.com, which operated an investment portal in 2001. His responsibility included content syndication, content generation and all sales activities. Since 2002 he has lead and participated various projects for the development of issuer services, some of those positioning and organizing the German Equity Forum and the introduction of the Entry Standard, the Deutsche Börse primary market offering with a focus on small and medium-sized companies. As senior vice president he was responsible for the Deutsche Börse listing activity in China. Since August

2010 he is responsible for the development of market segments, the relationship management towards listed companies and the acquisition of domestic and international companies for Deutsche Börse´s primary market.

12

Company Profile

As one of the world’s leading exchange organisations Deutsche Börse Group provides

investors, financial institutions and companies access to global capital markets. Our

business covers the entire process chain from securities and derivatives trading, clearing,

settlement and custody, through to market data and the development and operation of

electronic trading systems.

Our reliable systems and our integrity as a neutral provider form the basis of our business

philosophy. We operate to the most exacting standards to create products and services to

meet the needs of international financial markets. As a listed company we work to create

value for our customers and our shareholders.

The Deutsche Börse business model is based on liquidity of stock trading and by thus is

align with the interests of the listed company. Due to this Deutsche Börse is offering its

professional and efficient listing platform and services to facilitate the development of the

listed company entering the European market and to meet the need of investors.

The DZ BANK Group forms part of the German cooperative financial services network, which comprises more

than 1,100 local cooperative banks and is one of Germany‘s largest private-sector financial services

organizations measured in terms of total assets. Within the cooperative financial services network, DZ BANK

AG functions both as a central institution for over 900 cooperative banks and their 12,000 branch offices and

as a corporate bank. The DZ BANK Group includes Bausparkasse Schwäbisch Hall, DG HYP, DZ BANK

International, DZ PRIVATBANK Gruppe, R+V Versicherung, TeamBank, Union Investment Group, VR

LEASING, and various other specialized institutions. The collaboration between the companies in the

DZ BANK Group helps optimize the product portfolio available to the cooperative banks and their 30 million or

so clients. This combination of banking, insurance, home savings, and personal investment products and

services has a long and successful tradition in the cooperative financial services network. The specialized

institutions in the DZ BANK Group provide first-class, highly competitive products at reasonable prices within

their specific areas of expertise. This enables the cooperative banks in Germany to offer their clients a

comprehensive range of outstanding financial services.

DZ BANK also offers a full range of equity capital markets products and services. The product portfolio

includes e.g. initial public offerings, capital increases, convertible bonds, participation certificates, equity-

research and corporate actions like designated sponsoring, employee participation programs, share-buy-back-

programs, public take-over, going private, delisting, squeeze-outs, block trades, paying and depositary agent

as well as the conversion into registered shares.

Mayer Brown llpBockenheimer Landstraße 98 -10060323 Frankfurt am MainGermany

Mayer Brown LLP is a limited liability partnership established under the laws of the State of Illinois, U.S.A.

Americas | Asia | Europe | www.mayerbrown.com

Mayer Brown is a leading global law firm with offices in major cities across the Americas, Asia and Europe.

The unique opportunities and challenges of the international operating life sciences industry require specific legal know-how, technological expertise and international advice from an entrepreneurial perspective. Our clients include life sciences companies as well as regional and global banks, investment banks and other investors in the life sciences sector. Our geographic reach and on-the-ground presence in most of the world’s key business and finance centres allow us to assist our clients in structuring and coordinating cross-border transactions and other transnational legal matters. For example, we are known as the law firm that “opens doors and closes deals in Asia” – a point supported by the many awards we have won.

Our in-depth experience, gained by working across business areas and issues with life sciencescompanies and networking with leading industry organizations, provides us with the necessary insights for handling the legal and regulatory challenges facing the global pharmaceuticals, biotech and medical device industries.

For solutions with a future.

Your contacts:Dr. Dr. Adem Koyuncu, Partner, T: +49 221 5771 164, akoyuncu@mayerbrown.comDr. Ulrike Binder, Partner, T: +49 69 7941 1377, ubinder@mayerbrown.com

Please visit our websites:Life Sciences: www.mayerbrown.com/lifesciencesCapital Markets: www.mayerbrown.com/capitalmarketsAsia: http://www.mayerbrown.com/mayerbrownjsm

Global Solutions. Local Strength.

PricewaterhouseCoopers (PwC) ist eine der führenden Wirtschaftsprüfungs- und Beratungsgesellschaften in Deutschland. PwC berät und prüft führende Industrie- und Dienstleistungsunternehmen jeder Größe. In Deutschland hat PwC rund 9.000 Mitarbeiter in den Bereichen Wirtschaftsprüfung und prüfungsnahe Dienstleistungen (Assurance), Steuerberatung (Tax) sowie in den Bereichen Deals und Consulting (Advisory). Die Fachspezialisten der verschiedenen Geschäftsfelder arbeiten bereichsübergreifend zusammen und sind auch regional präsent. Rund 430 Partner und 6.700 Fachkräfte verfügen über umfassende Kenntnisse in allen wichtigen Branchen und bieten maßgeschneiderte Dienstleistungen aus einer Hand.

PwC ist aufgrund seines weltweiten Verbundes in der Lage, seinen Mandanten professionelle Dienstleistungen auf der ganzen Welt und eine grenzüberschreitende Betreuung zur Verfügung zu stellen. Als unabhängiges Mitglied dieses Netzwerkes kann PwC Deutschland auf die Unterstützung von rund 162.000 Mitarbeitern in 154 Ländern zugreifen. Wir begleiten Unternehmen in allen Entwicklungsphasen und helfen ihnen, auf den komplexer gewordenen Märkten erfolgreich zu sein – in Deutschland, Europa und auf der ganzen Welt.

Verband: BIO Deutschland e.V. Tegeler Weg 33 / berlinbiotechpark 10589 Berlin Web: www.biodeutschland.org Gesellschaftsform: eingetragener Verein Management: Dr. Viola Bronsema, Geschäftsführerin Jahr der Gründung: 2004 Tel.: +49-30-3450593-30 Fax: +49-30-3450593-59 E-Mail: info@biodeutschland.org Profil: BIO Deutschland, als der Branchenverband der Biotechnologie-Industrie, hat sich zum Ziel gesetzt, die Entwicklung eines innovativen Wirtschaftszweiges auf Basis der modernen Biowissenschaften zu unterstützen und zu fördern. Der mehr als 270 Mitglieder zählende Wirtschaftsverband mit Sitz in Berlin wird von einem zahnköpfigen Vorstand geleitet, der sich aus Vorstandsvorsitzenden und Geschäftsführern von Biotechnologie-Unternehmen sowie Geschäftsführern von Bioregionen zusammensetzt. Dieses Gremium repräsentiert umfassend die unterschiedlichen Bereiche der Branche. Die Mitgliedsunternehmen sind mit ihren Experten in Arbeitsgruppen organisiert, die sich mit folgenden Themengebieten beschäftigen: Finanzen und Steuern, Schutzrechte und technische Verträge, regulatorische Angelegenheiten, Innovation, Unternehmertum und Arbeitsplätze, Ausbildung und Arbeitsmarkt (HR), Deutsch&US-amerikanische Beziehungen, Gesundheitspolitik, Wettbewerb und Ordnungspolitik sowie Technologietransfer und Öffentlichkeitsarbeit. Mit einer ganzen Reihe politischer Initiativen setzt sich BIO Deutschland dafür ein, die gesetzlichen Rahmenbedingungen für den innovativen Mittelstand zu verbessern. BIO Deutschland ist die deutsche Vertretung der Biotechnologie-Branche in Brüssel beim europäischen Verband EuropaBio. Darüber hinaus arbeitet BIO Deutschland eng mit weiteren Biotech-Organisationen in Europa und den USA zusammen, um international koordiniert für die Interessen der Branche einzutreten. Auch auf dem Gebiet der Veranstaltungen ist der Verband auf vielfacher Weise tätig, um der Biotechnologie Plattformen zum Austausch und Interaktionen zu bieten.

The Biotechnologie-Industrie-Organisation Deutschland

(BIO Deutschland) with offices in Berlin is the independent industry association of German biotechnology companies. Founded in October 2004, BIO Deutschland currently has more than 270

member companies. To support its members BIO Deutschland is active on a wide range of measures like lobbying, public relations,

or offering business development opportunities and events.

BIO Deutschland

Tegeler Weg 33 | berlinbiotechpark | 10589 Berlin | Germany Tel: +49 30 3450593-30 | Fax +49 30 3450593-59

info@biodeutschland.org | www.biodeutschland.org

BIOCOM AG | Stralsunder Straße 58–59 | 13355 Berlin | Germanywww.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11

A AT T G A CAC ACG TTC GCC GAT AAG GAA G T T ATG GAA C C TGGA CCA TCA CGA TAA AAC GGA CAA T TA CCC GAT TGG AAAATC GAA ACC GAA TCA GCC AGT CAA GAA GCT TTC GAC T G CG TA T T G CAA GGC CAC CAG TAG CAC ACG TGC GGA ACG AC ATA A ACT GGA ACA AGA TCC AAA GCT T AT TGG AAG TGC CCGCCA STudieS & ConSulTinG GCA TAC CAA TGC ATG CAC GGAAGG TTC G TA T TA ACT AGA GAT CAT T C T AAC CCT TAT AGC GTT ConferenCeS AAG GAG ATC CCC TTG ACC GGC CGG T T TTCC CTC CTG GCG GTG TCA AAT CAG TGA CGA CCG T G T ACAACA BookSTC TCG CCA TA A CGT TGG C T T AAA GCT TAG GCCGCC ACG GAA ACG GGT GAC GGG A AT CCA ACC GAC AGA AT TTGA TV & VideoAC TCC GCA C AT TTG CGA GCT AGA ACG TA AGCC TAG GCT CAA AAC GCA TG T GCC G AT CAA GAA TGC AAGG AT CorporATe puBliShinG T T T GGA GAA C TA ACA T C T AGAATC CAG C T T ACC AGA TGC AAG AT C T TG GGA GGC AC T GAGG TA inTerneT CTC CGC ACG TCC A AT GGA ATC G TA TA A C C AAGG GTT TCC ACA GCC TGA GCC G AT ATC G TA AGG TGA CAAGAA MAGAzineSGA TTC GTC CTC AGT ACG TCA TAG CAA A C TCAC TC A ACC CAA GGA G T T G TA C TA CTG CGC GAA C T T ACGCGA eVenT MAnAGeMenTTA GCG TCG ACG CAC CAA TGC ACCGCC AAC GCC CAG TCC AT T AGA GAG TCA TA A GAC GCA GCACAA CAC GCT GT T CCC GGA TGC AC A GCC AGG ACT C T T TGCAGC GGC AAA GCA C AT CCA AGA GAA TGG GAC ACG TGC CACACC GGC GCA TG T TGA CAC AAT CAG CCT G AT TAG CAC CAGTA A GC T AGA CAA ACA T C T W e Cre AT e knoWledGe ! TGGAGT G T T CTC AAG GAA TGA CGA TG T GCC T TG ACC TCG ACGG T T ACT ACG TC C TGC ATG T TG CGA T TG GGA AGA AAA C T C

Biocom_A4_mr1.indd 1 27.04.2011 14:43:22 Uhr

Life Science Conference

Organizational Details

DVFA Center Mainzer Landstrasse 37-39 60329 Frankfurt am Main

It will be possible to reach you and the DVFA team during the conference at the following number:

Mobile: +49 / 178 / 401 4202 Phone: +49 / 69 / 24 24 94 08 Fax: +49 / 69 / 24 24 94 09

DVFA Center Mainzer Landstrasse 37-39 60329 Frankfurt am Main

Event Management Heike Hambuch eMail: hh@dvfa.de

Technical Support Viktor Bart eMail: vb@dvfa.de

DVFA GmbH Mainzer Landstrasse 47a 60329 Frankfurt am Main Phone: +49 / 69 / 26 48 48 0 Fax: +49 / 69 / 26 48 48 489 www.dvfa.de

Managing Director Ralf Frank eMail: rf@dvfa.de, Phone: +49 / 69 / 26 48 48 0

Financial Communication Karin Wenzel eMail: kw@dvfa.de, Phone: +49 / 69 / 26 48 48 101

Contact Details Life Science Conference

Contact Details DVFA GmbH

Venue

19

DVFAGmbHKarin WenzelFinancial CommunicationMainzer Landstrasse 47aD-60329 Frankfurt am MainTel.: +49 (0) 69 26 26 48 101Fax: +49 (0) 69 26 26 48 489Mail: kw@dvfa.deWeb: www.dvfa.de

Content: DVFA GmbHDesign: ReichDesign, FrankfurtPicture: www.shutterstock.com Subject to modifications. Copyright 2011 DVFA GmbH.

TargetGroupTarget group for the symposium are experts from the life science sector.

VenueDVFA CenterMainzer Landstrasse 37-39D-60329 Frankfurt am MainTel.: +49 (0) 69 24 24 94 08

DVFA–SocietyofInvestmentProfessionalsinGermany

DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently, DVFA has more than 1,200 individual members representing over 400 investment firms, banks, asset managers, consultants and counselling businesses. DVFA assures the credibility of the professionals and the integrity of the market by offering internationally recognised qualification programmes, by providing platforms for professional financial communication, and by effective self-regulation.

Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access to a pan-European network with more than 17,000 investment professionals in 26 nati-ons. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is part of a worldwide network of more than 60,000 investment professionals.